Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw

Stock analysts at Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) in a report released on Thursday, Marketbeat.com reports. The brokerage set a "buy" rating and a $9.00 price target on the stock. Rodman & Renshaw's price objective points to a potential upside of 210.34% from the stock's current price.

Eupraxia Pharmaceuticals Stock Up 2.1 %

Shares of EPRX stock traded up $0.06 on Thursday, reaching $2.90. 9,957 shares of the stock were exchanged, compared to its average volume of 15,385. Eupraxia Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $5.58. The stock has a market cap of $79.12 million and a P/E ratio of -4.03. The firm has a 50 day moving average of $2.65 and a two-hundred day moving average of $2.68.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

An institutional investor recently bought a new position in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC purchased a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 13,000 shares of the company's stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.